Zobrazeno 1 - 10
of 44
pro vyhledávání: ''
Autor:
Michael E. Mullendore, Deborah Wilsker, Anne Monks, Melinda G. Hollingshead, Lara H. El Touny, Sergio Y. Alcoser, Angie B. Dull, Curtis Hose, Erik Harris, Michelle M. Gottholm-Ahalt, Annamaria Rapisarda, Beverly A. Teicher, Ralph E. Parchment, James H. Doroshow, John Connelly
Publikováno v:
Oncotarget
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMTlow/−ve/MMRproficient patients benefit f
Autor:
Mikhail V. Blagosklonny
Publikováno v:
Oncotarget
Senolytics are basically anti-cancer drugs, repurposed to kill senescent cells selectively. It is even more difficult to selectively kill senescent cells than to kill cancer cells. Based on lessons of cancer therapy, here I suggest how to exploit onc
Autor:
Cory D. Fulcher, Carlos Thomas, Nicolas F. Schlecht, Michael B. Prystowsky, Bradley A. Schiff, Richard V. Smith, Andrea Lopez, Nicole Kawachi, Thomas J. Belbin, Gregory Rosenblatt, Evripidis Gavathiotis, Catherine Sarta, Geoffrey Childs, Chandan Guha, Thomas M. Harris, Denis E. Reyna, Thomas J. Ow, Pilib Ó Broin
Publikováno v:
Oncotarget
Mechanisms of treatment resistance in head and neck squamous cell carcinoma (HNSCC) are not well characterized. In this study, HNSCC tumors from a cohort of prospectively enrolled subjects on an ongoing tissue banking study were divided into those th
Autor:
Sweta Ghosh, Anamika Bose, Akata Saha, Suchandra Bhattacharyya Majumdar, Subrata Majumdar, Junaid Jibran Jawed, Sayantan Banerjee, Subir Kumar Juin, Kuntal Halder, Bidisha Paul Chowdhury, Rathindranath Baral
Publikováno v:
Oncotarget
// Sweta Ghosh 1 , Junaid Jibran Jawed 1 , Kuntal Halder 1 , Sayantan Banerjee 1 , Bidisha Paul Chowdhury 1 , Akata Saha 2 , Subir Kumar Juin 1 , Suchandra Bhattacharyya Majumdar 1 , Anamika Bose 2 , Rathindranath Baral 2 and Subrata Majumdar 1 1 Div
Autor:
Subaru Shintani, Osamu Nagano, Shogo Okazaki, Juntaro Yamasaki, Yuki Hirata, Kentaro Suina, Takashi Semba, Hideyuki Saya, Miyuki Ishikawa, Kiyoko Umene
Publikováno v:
Oncotarget
The cystine-glutamate antiporter subunit xCT suppresses iron-dependent oxidative cell death (ferroptosis) and is therefore a promising target for cancer treatment. Given that cancer cells often show resistance to xCT inhibition resulting in glutathio
Autor:
Samaresh Sau, Edi Levi, Mandip Singh, Hashem O. Alsaab, Vino T. Cheriyan, Magesh Muthu, Imran Vhora, Sreeja C. Sekhar, Jaganathan Venkatesh, Arun K. Rishi, Lisa Polin, Arun K. Iyer, Gerold Bepler, Arindam Mondal
Publikováno v:
Oncotarget
Non-small cell lung cancers (NSCLC) account for 85% of all lung cancers, and the epidermal growth factor receptor (EGFR) is highly expressed or activated in many NSCLC that permit use of EGFR tyrosine kinase inhibitors (TKIs) as frontline therapies.
Autor:
Colin H. Beckwitt, Yoshinao Z. Hosaka, Alan Wells, Takuro Ishikawa, Katsuhiko Warita, Zoltán N. Oltvai
Publikováno v:
Oncotarget
HMG-CoA reductase (HMGCR) inhibitors, statins, are potent cholesterol reducing drugs that exhibit anti-tumor effects in vitro and in animal models, including attenuation of metastasis formation, and their use correlates with reduced cancer-specific m
Autor:
Analia Lourdes Redondo, Angel Matias Sanchez, Fiorella Vanderhoeven, Laura M. Vargas-Roig, Ana Laura Martinez, Marina Ines Flamini
Publikováno v:
Oncotarget
Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis. Anti-HER2 strategies, such as the monoclonal antibody Trastuzumab (Tz), have theref
Publikováno v:
Oncotarget
Metformin exerts direct anti-tumor effects by activating AMP-activated protein kinase (AMPK), a major sensor of cellular metabolism in cancer cells. This, in turn, inhibits pro-survival mTOR signaling. Metformin has also been shown to disrupt complex
Autor:
Kevin F Chin, Timothy J. Yen, Vikram Bhattacharjee, Kayleigh C. Ross, Christopher D. Marion, Daehwan Kim
Publikováno v:
Oncotarget
Acquired resistance of metastatic melanoma (MM) tumors to BRAF V600E inhibitors (BRAFi’s) is commonplace in the clinic. Habitual relapse of patients contributes to